benzene-1,2-disulfonic acid anhydride | 33356-82-0

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: benzene-1,2-disulfonic acid anhydride
• 英文别名: Benzol-1,2-disulfonsaeure-anhydrid；Benzo-disulfonsaeureanhydrid；Benzoldisulfonsaeureanhydrid；2,1,3-Benzoxadithiole, 1,1,3,3-tetraoxide；2,1λ6,3λ6-benzoxadithiole 1,1,3,3-tetraoxide
• CAS: 33356-82-0
• 化学式: C₆H₄O₅S₂
• 分子量: 220.227
• InChiKey: QTLDNGFPYAWPLR-UHFFFAOYSA-N

物化性质

• 沸点：
  434.0±28.0 °C(Predicted)
• 密度：
  1.794±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzene-1,2-disulfonic acid anhydride 在 sodium acetate 、 溶剂黄146 作用下， 生成 苯二磺酸
  参考文献：
  名称：

  Sanecki, Przemyslaw; Rokaszewski, Edward, Canadian Journal of Chemistry, 1987, vol. 65, p. 2263 - 2267

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2-苯二磺酰二氯 在 sodium acetate 、 溶剂黄146 作用下， 生成 benzene-1,2-disulfonic acid anhydride
  参考文献：
  名称：

  Sanecki, Przemyslaw; Rokaszewski, Edward, Canadian Journal of Chemistry, 1987, vol. 65, p. 2263 - 2267

  摘要：

  DOI：

文献信息

• Transfer hydrogenation process and catalyst
  申请人：——

  公开号：US20040102313A1

  公开（公告）日：2004-05-27

  A catalytic transfer hydrogenation process is provided. The catalyst employed in the process is a metal hydrocarbyl complex which is coordinated to defined bidentate ligands substituted with at least one group selected from an optionally substituted sulphonated hydrocarbyl group, a sulphonated perhalogenated hydrocarbyl group, or an optionally substituted sulphonated heterocyclyl group. Preferred metals include rhodium, ruthenium and iridium. Preferred bidentate ligands are diamines and aminoalcohols, particularly those comprising chiral centres. The hydrogen donor is advantageously a secondary alcohol or a mixture of triethylamine and formic acid. The process can be employed to transfer hydrogenate ketones and imines, which are preferably prochiral. Catalysts for use in such a process are also provided.

  提供了一种催化转移加氢过程。该过程中所使用的催化剂是一种金属烃基配合物，其与定义的双齿配体配位，该配体中至少有一个基团被选自可选择替代的磺化烃基团、磺化全氟烃基团或可选择替代的磺化杂环烃基团。优选金属包括铑、钌和铱。优选的双齿配体是二胺和氨基醇，特别是那些含手性中心的配体。氢供体优选是二级醇或三乙胺和甲酸的混合物。该过程可用于转移加氢酮和亚胺，这些酮和亚胺最好是可拆性的。还提供了用于这种过程的催化剂。
• Electrolytic solution for nonaqueous electrolytic solution secondary batteries and nonaqueous electrolytic solution secondary battery
  申请人：Central Glass Company, Ltd.

  公开号：US11114693B2

  公开（公告）日：2021-09-07

  A nonaqueous electrolytic solution contains a nonaqueous solvent and an electrolyte dissolved in the solvent. The solution includes a difluoro ionic complex (1-Cis) in a cis conformation represented by the formula (1-Cis), and at least one of cyclic sulfonic acid ester, cyclic sulfonic acid ester having an unsaturated bond, cyclic sulfuric acid ester, cyclic disulfonic acid ester, chain disulfonic acid ester, cyclic disulfonic acid anhydride, nitrile group-containing compound, silyl phosphate ester derivative, and silyl borate ester derivative.

  一种非水电解质溶液包含一个非水溶剂和一个在溶剂中溶解的电解质。该溶液包括一种二氟离子复合物(1-Cis)，其处于顺式构象，由式(1-Cis)表示，并且至少包括以下一种：环状磺酸酯，带有不饱和键的环状磺酸酯，环状硫酸酯，环状二磺酸酯，链状二磺酸酯，环状二磺酸酐，含氰基的化合物，硅酸酯磷酸酯衍生物和硅酸酯硼酸酯衍生物。
• Aminoguanidines and alkoxyguanidines as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20010037039A1

  公开（公告）日：2001-11-01

  Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: 1 wherein X is O or NR 9 and R 1 —R 4 , R 6 —R 9 , R 11 , R 12 , R a , R b , R c , Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula . The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

  描述了氨基胍和烷氧基胍化合物，包括式子：1中X为O或NR9，R1-R4、R6-R9、R11、R12、Ra、Rb、Rc、Y、Z、n和m在规范中给出，以及其水合物、溶剂化合物或药物可接受的盐，这些化合物抑制蛋白酶酶，如凝血酶。还描述了制备公式化合物的方法。本发明的新型化合物是蛋白酶的有效抑制剂，特别是类似胰蛋白酶的丝氨酸蛋白酶，如胰蛋白酶、凝血酶、纤溶酶和Xa因子。其中某些化合物通过直接、选择性地抑制凝血酶表现出抗血栓活性，或者是用于制备具有抗血栓活性的化合物的中间体。本发明包括一种组合物，用于抑制哺乳动物中的血小板丢失、抑制血小板聚集的形成、抑制纤维蛋白的形成、抑制血栓形成和抑制栓塞形成，包括本发明中的化合物和药物可接受的载体。本发明化合物的其他用途是作为抗凝剂，嵌入或物理连接到用于血液采集、血液循环和血液储存的设备中使用的材料中，如导管、血液透析机、血液采集注射器和管、血液管路和支架。
• Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040002539A1

  公开（公告）日：2004-01-01

  Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: 1 wherein X is O or NR 9 and R 1 -R 4 , R 6 -R 9 , R 11 , R 12 , R a , R b , R c , Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula L The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

  本发明涉及氨基胍和烷氧基胍化合物，包括以下式子的化合物：1其中X为O或NR9，R1-R4、R6-R9、R11、R12、Ra、Rb、Rc、Y、Z、n和m在说明书中给出，以及其水合物、溶剂合物或药学上可接受的盐，其抑制蛋白酶如凝血酶。还描述了制备式L化合物的方法。本发明的新化合物是蛋白酶的强力抑制剂，尤其是类胰蛋白酶，如胰蛋白酶、凝血酶、纤溶酶和Xa因子。其中某些化合物通过直接、选择性抑制凝血酶表现出抗血栓活性，或者是用于形成具有抗血栓活性的化合物的中间体。本发明包括一种用于抑制哺乳动物体内血小板丧失、抑制血小板聚集、抑制纤维蛋白形成、抑制血栓形成和抑制栓塞形成的组合物，其中包括本发明中的化合物和药学上可接受的载体。本发明化合物的其他用途是作为抗凝剂，嵌入或物理链接到用于血液收集、血液循环和血液储存的设备制造中使用的材料中，如导管、血液透析机、血液采集注射器和管道、血液输送管和支架等。
• Verfahren zur Herstellung von Dispersionen hydrophober Farbkuppler in Wasser sowie deren Verwendung bei der Herstellung lichtempfindlicher Aufzeichnungsmaterialien
  申请人：Agfa-Gevaert AG

  公开号：EP0049399A2

  公开（公告）日：1982-04-14

  Dispersionen hydrophober Substanzen in Wasser werden hergestellt, indem man die hydrophobe Substanz zusammen mit einem ionomeren Polyadditions- oder Kondensations-produkt in einem organischen, mit Wasser mischbaren Lösungsmittel oder einer Mischung des Lösungsmittels mit Wasser löst, Wasser zusetzt und das Lösungsmittel entfernt. Die so hergestellten Dispersionen werden mit Vorteil bei der Herstellung photographischer Aufzeichnungsmaterialien verwendet.

  疏水性物质在水中的分散体的制备方法是：将疏水性物质与离子聚合体或缩合产物一起溶解在有机水溶性溶剂或溶剂与水的混合物中，然后加水并除去溶剂。用这种方法制得的分散体可用于生产照相记录材料。